| Tavalisse (fostamatinib) / Rigel |
NCT02611063: Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant |
|
|
| Completed | 1 | 22 | US | fostamatinib | Stefanie Sarantopoulos, MD, PhD. | Hematological Malignancies | 02/21 | 02/22 | | |
NCT03246074: Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer |
|
|
| Active, not recruiting | 1 | 35 | US | Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib and Abraxane, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Rigel Pharmaceuticals, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Ovarian Cancer | 08/22 | 10/24 | | |
NCT05904093: Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease |
|
|
| Not yet recruiting | 1 | 25 | US | Fostamatinib | National Heart, Lung, and Blood Institute (NHLBI) | Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease | 08/25 | 05/26 | | |
NCT06233110: Ruxolitinib Plus Fostamatinib for Steroid Refractory CGvHD |
|
|
| Not yet recruiting | 1 | 30 | US | Fostamatinib, Ruxolitinib | Stefanie Sarantopoulos, MD, PhD., Incyte Corporation, Rigel Pharmaceuticals, National Institutes of Health (NIH) | Chronic Graft Versus Host Disease | 01/29 | 07/29 | | |
NCT05030675: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents |
|
|
| Completed | 1 | 11 | US | Fostamatinib, R-935788 Free Acid, R788 Free Acid | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | 08/24 | 08/24 | | |
